RECOMBINANT LEUKOCYTE ALPHA INTERFERON IN NON-HODGKIN'S LYMPHOMA PATIENTS

生物反应调节剂计划的先前研究和 其他地方已经证明了重组阿尔法的显著活性 复发性非霍奇金淋巴瘤患者的干扰素治疗 淋巴瘤和一些弥漫性低分化淋巴瘤患者。 然而，参加这项试验的大多数患者都需要减少剂量。 因为毒性过大。与初步研究同时进行的研究 其他机构的淋巴瘤研究表明， 极低剂量重组α-干扰素治疗毛细胞病 白血病，另一种慢性B细胞肿瘤。当前的目的是 试验是确定组织学良好的非霍奇金氏病患者 淋巴瘤会对较低剂量的干扰素产生反应，发现 对毛细胞白血病患者有效。的第二个目标 试验是进一步评估大剂量重组阿尔法的疗效。 干扰素对弥漫性低分化淋巴瘤患者的影响 这些患者中只有一小部分人在初步试验中得到了治疗。 试验的第三个目标是试图确定低剂量 重组α干扰素对慢性粒细胞白血病患者有效 最近描述的T-γ淋巴增生性疾病，一种T细胞的疾病 在许多方面与毛细胞白血病相似的细胞。

Previous investigations in the Biological Response Modifiers Program and elsewhere have demonstrated significant activity of recombinant alpha interferon in patients with relapsed favorable histology non-Hodgkin's lymphoma and in some patients with diffuse poorly differentiated lymphoma. Most patients entered on this trial, however, require dose reductions because of excessive toxicity. Studies done concurrently with the initial lymphoma studies at other institutions demonstrate significant activity of very low doses of recombinant alpha interferon in patients with hairy cell leukemia, another chronic B-cell neoplasm. The purpose of the current trial was to determine if patients with favorable histology, non-Hodgkin's lymphoma would respond to the lower doses of interferon found to be very effective in patients with hairy cell leukemia. A second objective of the trial was to further evaluate the efficacy of high dose recombinant alpha interferon in patients with diffuse poorly differentiated lymphoma since only small numbers of these patients had been treated in the intial trial. The third objective of the trial was to attempt to determine if low doses of recombinant alpha interferon would be effective in patients with the recently described T gamma lymphoproliferative disorder, a disorder of T cells that resembles in many regards hairy cell leukemia.